Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. No statements or discussions about raising capital through funding rounds or debt instruments are present. The focus is on organic growth, acquisitions (like the 51% stake in Saarathi Healthcare), and business expansion. Strategic growth is driven by increasing product portfolio, expanding service offerings, and scaling operations rather than fundraising efforts. Investors are encouraged to connect for meetings, but no fundraising plans are disclosed in this call.

Any current/future capex/capital investment/strategic investment?

QMS Medical Allied Services does not have its own manufacturing facilities; it relies entirely on third-party vendors trusted and quality-approved by IIT Mumbai. The company has recently acquired a 51% stake in Saarathi Healthcare Private Limited, marking a strategic expansion. They have acquired a government business model from the Chhattisgarh government related to TB patient services, expanding their patient service segment. There is a focus on expanding the product portfolio significantly—from around 38-40 products currently to aiming for 100 products within a year. Investment is directed

Future growth expectations in sales/revenue/volumes?

QMS Medical Allied Services aims for steady growth of 15-25% annually. Additional growth expected from expansion into hospital sectors and government business collaborations (e.g., Saarathi Healthcare and Chhattisgarh government TV screening programs). Online business, though new (approx. 145 days), shows promising outlook with plans to increase product portfolio from current ~40 to 100 products covering health and wellness. Shift from product sales to solutions ecosystem is improving operating margins. Plans to scale private brand sales significantly, targeting around ₹10 crores annually, lev

Future growth expectations in earnings/operating earnings/profits/EPS?

QMS Medical Allied Services targets steady growth of 15-25% annually. FY24 revenue was around ₹122 crores with EBITDA margin of 15.3%. Q1 FY25 operating revenue grew 22% QoQ to ₹30.37 crores; net profit grew 56% QoQ to ₹2.4 crores. Operating income improved 17% YoY; EBITDA rose 4% YoY in Q1 FY25. Margin growth driven by shift from product sales to higher-margin solutions/services. Expansion plans include increasing private brand product offerings from 38-40 to 100 SKUs within a year. Acquisition of 51% stake in Saarathi Healthcare adds new government business streams. Online and e-commerce sal

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in specific numbers. The company is expanding through acquisitions, such as the recent 51% acquisition in Saarathi Healthcare Private Limited. They have a government business model in Chhattisgarh with TB patient screening programs. The company is scaling its services and products with plans to increase its product portfolio from about 38-40 items to 100 within a year. Growth is projected at around 15-25% annually, with additional contributions expected from hospital and government segments. New bus

QMS MedicalQ1 FY25Healthcare Equipment & Supplies

QMS Medical Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹196P/E: 35.4Market Cap: ₹380 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

QMS Medical Allied Services aims for steady growth of 15-25% annually.
Additional growth expected from expansion into hospital sectors and government business collaborations (e.g., Saarathi Healthcare and Chhattisgarh government TV screening programs).
Online business, though new (approx. 145 days), shows promising outlook with plans to increase product portfolio from current ~40 to 100 products covering health and wellness.
Shift from product sales to solutions ecosystem is improving operating margins.
Plans to scale private brand sales significantly, targeting around ₹10 crores annually, leveraging B2B and online retail channels.
Service models have better margins than product sales, expected to contribute more to revenue growth.
Overall, QMS anticipates growth both from expanding product offerings and scaling service-driven patient programs across India.

Margin guidance

Category 3

QMS Medical Allied Services targets steady growth of 15-25% annually.
FY24 revenue was around ₹122 crores with EBITDA margin of 15.3%.
Q1 FY25 operating revenue grew 22% QoQ to ₹30.37 crores; net profit grew 56% QoQ to ₹2.4 crores.
Operating income improved 17% YoY; EBITDA rose 4% YoY in Q1 FY25.
Margin growth driven by shift from product sales to higher-margin solutions/services.
Expansion plans include increasing private brand product offerings from 38-40 to 100 SKUs within a year.
Acquisition of 51% stake in Saarathi Healthcare adds new government business streams.
Online and e-commerce sales expected to drive distribution and sales growth.
New service verticals in areas like cardiac, diabetic retinopathy expected to boost future revenue and margins.

See what QMS Medical management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising through debt or equity.
No statements or discussions about raising capital through funding rounds or debt instruments are present.
The focus is on organic growth, acquisitions (like the 51% stake in Saarathi Healthcare), and business expansion.
Strategic growth is driven by increasing product portfolio, expanding service offerings, and scaling operations rather than fundraising efforts.
Investors are encouraged to connect for meetings, but no fundraising plans are disclosed in this call.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in specific numbers.
The company is expanding through acquisitions, such as the recent 51% acquisition in Saarathi Healthcare Private Limited.
They have a government business model in Chhattisgarh with TB patient screening programs.
The company is scaling its services and products with plans to increase its product portfolio from about 38-40 items to 100 within a year.
Growth is projected at around 15-25% annually, with additional contributions expected from hospital and government segments.
New business models and government projects (such as the TB program) indicate a growing order pipeline supporting future revenue growth.

See what QMS Medical management said on order book — free account, 30 seconds.

Capex plans

Yes

QMS Medical Allied Services does not have its own manufacturing facilities; it relies entirely on third-party vendors trusted and quality-approved by IIT Mumbai.
The company has recently acquired a 51% stake in Saarathi Healthcare Private Limited, marking a strategic expansion.
They have acquired a government business model from the Chhattisgarh government related to TB patient services, expanding their patient service segment.
There is a focus on expanding the product portfolio significantly—from around 38-40 products currently to aiming for 100 products within a year.
Investment is directed towards service business growth, including equipment like diabetic retinopathy machines, Hb1C machines, and BMD machines (each costing approximately ₹8 lakh).
The company is expanding its hospital billing and hospital segment operations.
Online business expansion forms a part of future strategy, leveraging e-commerce platforms to reach wider markets.

Track QMS Medical — get its next earnings analysis in your feed

How does QMS Medical rank vs peers in Healthcare Equipment & Supplies?

Pro feature

ThisQMS Medical

Rev 3Mar 3

See where QMS Medical sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

How does QMS Medical rank in Healthcare Equipment & Supplies?

Compare QMS Medical against every Healthcare Equipment & Supplies company (Q1 FY25) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

What QMS Medical's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

Fischer Medical Ventures Ltd (Q2 FY25)
EBITDA: ₹36.3 crore, a 45.5% year-on-year increase. Key concall takeaways from Fischer Medical Ventures Ltd's Q2 FY25 earnings call — and how it ranks against…
Fischer Medical Ventures Ltd (Q1 FY27)
The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…
OSEL Devices Ltd (Q1 FY26)
FY25 total income (revenue) was ₹18,660.07 lakhs, up 41% YoY from ₹13,268.52 lakhs in FY24. Key concall takeaways from OSEL Devices Ltd's Q1 FY26 earnings call…
Q-Line Biotech Ltd (Q4 FY26)
Shift towards more manufacturing with gross margins of 60-65% for reagents supporting profitability improvement (Page 7, 6). Key concall takeaways from Q-Line…

Compare:vs Poly Medicure Ltd vs Molbio Diagnosti vs Fischer Medical Ventures Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

QMS Medical Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does QMS Medical rank in Healthcare Equipment & Supplies?

Continue your research

What QMS Medical's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season